Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics is a company that does not yet have a drug on the market. Instead, it has a portfolio of compounds in various stages of development, with the most advanced candidates in Phase II clinical trials. The company is betting that one or more of these will eventually win regulatory approval and generate substantial revenue. Until that happens, Viking exists on capital raises and partnerships that fund its research operations. The business is entirely optionality: the value hinges on whether any of its experimental drugs prove safe and effective in humans, secure regulatory approval, and capture market share in their indication.

The company’s therapeutic focus is metabolic and cardiovascular disease — obesity, type-2 diabetes, fatty liver disease, and related conditions. This is one of the hottest areas in pharma right now. The commercial success of drugs like semaglutide (Ozempic, Wegovy) for weight loss has sparked enormous investor interest in the obesity and metabolic disease space. Dozens of companies are now racing to develop competing treatments. Viking is one of them, but without an approved drug or even a late-stage candidate in the pipeline, it is early compared to larger rivals and some better-funded peers.

The founding thesis and strategic focus

Viking was founded in 2012 by physicians and researchers with expertise in metabolic disease. The company’s early strategy was to build a discovery and development engine around small-molecule drugs — pills that people take by mouth, as opposed to injectable biologics or monoclonal antibodies. Small molecules have advantages: they are cheaper to manufacture, easier to distribute, and generally more acceptable to patients than injections. They also have challenges: they are harder to design to hit a specific target with high selectivity, and oral bioavailability (the percentage of the drug that actually reaches the bloodstream after swallowing) can be difficult to achieve.

The obesity and metabolic disease market has been defined for years by GLP-1 receptor agonists — a class of injectables (semaglutide, tirzepatide) that suppress appetite and improve metabolic control. These drugs are blockbusters and have created enormous patient demand. But they are injectables, expensive, and not suitable for everyone. Viking’s thesis is that oral small-molecule alternatives could capture a large subset of that market by offering ease of administration and lower cost.

The pipeline and stage of development

Viking’s most advanced candidate is VK2735, an oral compound that activates dual receptors in the GLP-1 and GCG pathways. The company has disclosed Phase II data suggesting weight loss and metabolic improvements in obese patients, which has generated investor interest and media attention. But Phase II is early — these trials are typically small (hundreds of patients) and short-term (weeks to a few months). They establish proof of concept but do not confirm safety or efficacy at scale or over longer periods.

For VK2735 to reach the market, Viking must conduct Phase III trials — larger, longer-duration studies that serve as the primary evidence for regulatory approval. These trials take years and cost hundreds of millions of dollars. If VK2735 advances successfully through Phase III, the company could file for FDA approval sometime in the mid-to-late 2020s (assuming no major delays). But large Phase III trials often uncover safety signals or efficacy gaps that send candidates back to the drawing board or kill them outright.

Beyond VK2735, Viking has earlier-stage candidates targeting obesity, fatty liver disease, and other metabolic indications. These are in preclinical development or Phase I trials — many years away from potential approval, if they ever get there. For a clinical-stage biotech company, the “pipeline” is often more marketing aspiration than real asset; most preclinical and Phase I molecules never see a patient in a Phase III trial.

Capital intensity and the burn rate

Developing drugs is capital-intensive. Clinical trials alone can cost hundreds of millions of dollars per candidate. Manufacturing, regulatory interactions, safety monitoring — it all adds up. Viking, like most clinical-stage biotechs, is spending more money each year than it brings in through revenue (because it has no approved drugs, it has essentially zero revenue). The company funds operations through a combination of venture capital, private equity, debt, and periodic secondary offerings (selling new shares to raise cash).

How long can Viking operate at its current burn rate given its cash position? This is the central question for any pre-revenue biotech. If cash runs out before a major milestone — like positive Phase III data or a partnership deal — the company must raise capital immediately or risk dilution of existing shareholders or, in extremis, inability to fund its programs. Biotech investors track cash-to-burn-rate ratios obsessively because it determines how much runway a company has.

The competitive melee and market dynamics

The obesity drug space has become crowded. Beyond Novo Nordisk (semaglutide, tirzepatide) and Eli Lilly (tirzepatide), dozens of smaller companies — Amgen, Viking, Viking competitors Rhythm Biosciences, Structure Therapeutics, Viking rival Carmot Therapeutics (now Roche), and others — are developing competing treatments. Some are further along than Viking; many are not. But the sheer number of competitors means the market will fragment if many of these drugs reach approval. First movers and those with strong efficacy/safety data will take the largest share.

Viking’s advantage is its small-molecule approach: if the company can demonstrate that an oral pill works as well as injections for obesity, it would capture patients who prefer pills to injections. The disadvantage is that semaglutide and tirzepatide are already approved, marketed, and reimbursed by insurance. Any new entrant must prove superiority or provide clear advantages (lower cost, fewer side effects, better efficacy) to gain meaningful market share.

The patent landscape also matters. GLP-1 and GCG receptor mechanisms are well-characterized and broadly known. Viking’s intellectual property relies on specific chemical structures and claims around its compounds. Larger pharma companies could potentially design around Viking’s patents, and competitors with stronger IP portfolios could block Viking from certain approaches. Patent strength and enforceability in the obesity space will likely see litigation in the next decade.

Partnership and collaboration risks

Smaller biotech companies like Viking often seek partnerships with larger pharma firms to fund late-stage trials and commercialisation. A partnership deal can provide billions in funding and bring a large sales force and distribution network to bear. But partnerships also mean giving up profit margins and control: the partner typically takes a large royalty on any sales, and decision-making becomes more complex.

Has Viking pursued partnerships? As of recent cycles, the company has sought collaborations but not signed major deals. Without a partner, Viking must fund Phase III trials on its own or through capital raises, which is capital-intensive and dilutive. Conversely, the upside if Viking’s compounds work is larger if the company retains rights, because it keeps more of the profit.

The research question: do the compounds work at scale?

Ultimately, Viking trades on a binary bet: will one or more of its compounds prove safe and effective in large Phase III trials? The data from Phase II is encouraging to believers, but Phase III is where many promising compounds fail. Different populations, longer durations, and larger patient numbers can reveal adverse effects that smaller trials missed. Manufacturing and supply-chain issues can delay trials. Patient recruitment can prove harder than expected. Regulatory feedback can require additional studies.

Viking’s management is experienced in drug development, and that is a modest advantage. But experience does not guarantee success. Hundreds of experienced drug developers have launched clinical programs that ultimately failed. Biotech is a domain where the best science and smartest teams often lose to bad luck, bad timing, or biology that simply does not cooperate.

How to research Viking as an investment

Viking’s 10-K (SEC CIK 0001607678) shows cash position, quarterly burn rate, and key milestones in the development timeline. Calculate the company’s cash runway: at the current burn rate, how many quarters does the cash last? If a Phase III trial is 2-3 years away and cash runs out in 18 months, the company will need to raise capital (dilutive to existing shareholders) or find a partner.

Track announcements of clinical trial results. When VK2735 or other candidates release data, watch for efficacy signals, safety concerns, and guidance on next steps. A major adverse event, even in a small patient population, can derail a program.

Monitor the obesity drug competitive landscape. How many other small-molecule competitors are in late-stage development? How many are further along than Viking? Market competition will determine pricing power and market share available to Viking if it succeeds.

Watch for partnership announcements. If Viking signs a partnership with a larger pharma company, it validates the compound but also signals that the partner sees commercial potential — and that capital is no longer an existential risk for Viking. Lack of partnership interest after Phase II could signal doubt about the compounds’ prospects.

Finally, follow regulatory interactions. The FDA provides feedback to companies during drug development. Positive interactions (the FDA agrees with the development plan) are good news; requests for additional studies or concerns about a mechanism are red flags.